Supernus Pharmaceuticals Faces Patent Challenges for Qelbree

Supernus Pharmaceuticals ( (SUPN) ) has provided an update.

On May 22 and 23, 2025, Supernus Pharmaceuticals received Paragraph IV Notice Letters indicating that third parties filed Abbreviated New Drug Applications (ANDAs) for viloxazine hydrochloride capsules, challenging the patents of their product Qelbree. Supernus plans to enforce its intellectual property rights, which are protected by six U.S. patents expiring between 2029 and 2035, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (SUPN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.

Spark’s Take on SUPN Stock

According to Spark, TipRanks’ AI Analyst, SUPN is a Neutral.

Supernus Pharmaceuticals scores well on financial performance due to strong margins, liquidity, and low leverage. However, mixed technical indicators and a high P/E ratio weigh on the overall score. The earnings call emphasized product growth, but legacy declines and losses present challenges.

To see Spark’s full report on SUPN stock, click here.

More about Supernus Pharmaceuticals

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its portfolio includes treatments for ADHD, Parkinson’s disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea, with ongoing development of new CNS treatments.

Average Trading Volume: 563,757

Technical Sentiment Signal: Hold

Current Market Cap: $1.83B

For an in-depth examination of SUPN stock, go to TipRanks’ Stock Analysis page.